David is a member of Valo's Board of Directors. Most recently, David served as Seagen's Chief Executive Officer and member of its Board until its acquisition by Pfizer in 2023. Prior to Seagen, he was an Executive Partner at Flagship Pioneering. From 2010 to mid-2016 he served as chief executive officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units.

David has more than 30 years of drug development, deal making, commercialization and leadership experience on a global scale. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx, and Entresto. He was named by FierceBiotech as one of the “25 most influential people in biopharma.” Early in his career, David was an associate in the strategy practice of consulting firm Booz, Allen and Hamilton.

David holds a BS in pharmacy from Rutgers University College of Pharmacy (1984) and an MBA in finance and marketing from the Columbia University Graduate School of Business (1987). He serves as a member of the board of directors for OPY Acquisition Corp. I, Woolsey Pharma, South Florida’s Pelican Harbor Seabird Station, and Tempus. David also serves on the Healthcare Advisory Board of J.P. Morgan Life Sciences Private Capital.